drugset / Trial / NCT03481400

CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment

NCT03481400

Unknown 40 enrolled Danish Headache Center
RandomizedCrossoverDouble-blindOther

Summary

The investigators aim to investigate the incidence of migraine attacks after calcitonin gene-related peptide (CGRP) infusion in patients who have tried anti-CGRP monoclonal antibody treatment for the prevention of migraine.

Timeline

Start
2016-07
Primary completion
2019-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitonin Gene-Related Peptide Peptide 1.5 ug Intravenous

Indications